Hansa Biopharma AB (HNSBF)
3.289
0.00 (0.00%)
USD |
OTCM |
Oct 08, 16:00
Hansa Biopharma EPS Diluted (Quarterly) : -0.279 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.279 |
| March 31, 2026 | -0.2111 |
| December 31, 2025 | -0.1724 |
| September 30, 2025 | -0.1838 |
| June 30, 2025 | -0.2878 |
| March 31, 2025 | -0.0537 |
| December 31, 2024 | -0.3781 |
| September 30, 2024 | -0.1469 |
| June 30, 2024 | -0.3091 |
| March 31, 2024 | -0.3992 |
| December 31, 2023 | -0.2215 |
| September 30, 2023 | -0.4421 |
| June 30, 2023 | -0.4544 |
| March 31, 2023 | -0.3752 |
| December 31, 2022 | -0.2973 |
| September 30, 2022 | -0.3272 |
| June 30, 2022 | -0.3881 |
| March 31, 2022 | -0.3332 |
| December 31, 2021 | -0.4145 |
| September 30, 2021 | -0.3858 |
| June 30, 2021 | -0.3544 |
| March 31, 2021 | -0.2781 |
| December 31, 2020 | -0.2763 |
| Date | Value |
|---|---|
| September 30, 2020 | -0.3128 |
| June 30, 2020 | -0.2562 |
| March 31, 2020 | -0.2409 |
| December 31, 2019 | -0.288 |
| September 30, 2019 | -0.2456 |
| June 30, 2019 | -0.2179 |
| March 31, 2019 | -0.1975 |
| December 31, 2018 | -0.2294 |
| September 30, 2018 | -0.1802 |
| June 30, 2018 | -0.1786 |
| March 31, 2018 | -0.1516 |
| December 31, 2017 | -0.1635 |
| September 30, 2017 | -0.1315 |
| June 30, 2017 | -0.1466 |
| March 31, 2017 | -0.1435 |
| December 31, 2016 | -0.1103 |
| September 30, 2016 | -0.0974 |
| June 30, 2016 | -0.1145 |
| March 31, 2016 | -0.0721 |
| December 31, 2015 | -0.0692 |
| September 30, 2015 | -0.0507 |
| June 30, 2015 | -0.0831 |
| March 31, 2015 | -0.0491 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| BioArctic AB | -0.0134 |
| Swedish Orphan Biovitrum AB | 0.1673 |
| Diamyd Medical AB | -0.0909 |
| BONESUPPORT HOLDING AB | 0.1309 |
| BioInvent International AB | -0.1995 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -27.82M |
| Revenue (Quarterly) | 5.136M |
| Total Expenses (Quarterly) | 32.96M |
| Enterprise Value | 377.72M |
| Gross Profit Margin (Quarterly) | 53.57% |
| Profit Margin (Quarterly) | -541.7% |
| Earnings Yield | -25.73% |
| Normalized Earnings Yield | -25.03 |